|View printer-friendly version|
|April 29, 2004 5:04 p.m.|
|Teva Announces Approval Of Fludarabine Phosphate Injection|
Jerusalem, Israel, April 29, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted approval for an ANDA for Fludarabine Phosphate Injection, 25 mg/ml, which was submitted by the Company's subsidiary Sicor Inc. Shipment of this product is expected to begin in the near future.